Trexquant Investment LP Immuno Gen, Inc. Transaction History

Trexquant Investment LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$14.09 - $19.87 $1.74 Million - $2.45 Million	123,379 Added 159.47%	200,746 $3.19 Million
Q2 2023 Aug 11, 2023	BUY	$3.75 - $20.05 $290,126 - $1.55 Million	77,367 New	77,367 $1.46 Million
Q2 2022 Aug 11, 2022	SELL	$3.15 - $5.76 $337,446 - $617,045	-107,126 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$4.26 - $7.48 $7,893 - $13,860	-1,853 Reduced 1.7%	107,126 $510,000
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $408,248 - $644,602	85,947 Added 373.16%	108,979 $809,000
Q3 2021 Nov 12, 2021	SELL	$5.02 - $6.59 $43,528 - $57,141	-8,671 Reduced 27.35%	23,032 $131,000
Q2 2021 Aug 12, 2021	SELL	$5.79 - $8.6 $45,879 - $68,146	-7,924 Reduced 20.0%	31,703 $209,000
Q1 2021 May 13, 2021	SELL	$6.5 - $10.53 $286,585 - $464,267	-44,090 Reduced 52.67%	39,627 $321,000
Q4 2020 Feb 11, 2021	BUY	$3.7 - $7.66 $309,752 - $641,272	83,717 New	83,717 $540,000
Q2 2018 Aug 07, 2018	SELL	$9.52 - $12.15 $3.15 Million - $4.02 Million	-331,215 Closed	0 $0
Q1 2018 May 03, 2018	BUY	$6.7 - $12.95 $1.46 Million - $2.81 Million	217,244 Added 190.61%	331,215 $3.48 Million
Q4 2017 Feb 09, 2018	BUY	$5.07 - $7.92 $47,343 - $73,956	9,338 Added 8.92%	113,971 $731,000
Q3 2017 Nov 09, 2017	BUY	$5.4 - $8.47 $565,018 - $886,241	104,633	104,633 $800,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.